Login / Signup

Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.

Eva M M StrijbisM W KochB A de Jong
Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
Keyphrases
  • mass spectrometry
  • multiple sclerosis
  • ms ms
  • bone marrow
  • mesenchymal stem cells
  • replacement therapy